Clinical trials: Recurrent or Metastatic NPC
Nasopharyngeal Carcinoma, Leucogen
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
Toxic and side effects during and after chemoradiotherapy for nasopharyngeal carcinoma seriously affect patients' treatment compliance and long-term quality of life.
- Conditions
- Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression
- Trial name
- NCT05780294
- Testing
- 5-fu, Lobaplatin, leucogen
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment.
- Trial name
- NCT00896675
- Testing
- proteomic profiles
- Where
- 3 sites in United States
- Volunteers
- 352 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Nasopharyngeal Neoplasms
Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy
This is a pilot phase II study of locally advanced or metastatic nasopharyngeal carcinoma (NPC) with the single drug Alimta. The objective of this study is to assess efficacy and safety profiles of Alimta as 2nd line treatment…
- Trial name
- NCT00630149
- Testing
- Pemetrexed (Alimta)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Locally Recurrent Cancer, Metastatic Nasopharyngeal Cancer
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- 2018/00947 (NCT03813394)
- Testing
- pembrolizumab, bevacizumab
- Where
- Singapore
- Volunteers
- 48 people
- Sponsor
- National University Hospital, Singapore
Recurrent or Metastatic Nasopharyngeal Carcinoma
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
This is a prospective, Bayesian adaptive, phase II clinical trial designed to evaluate the safety and efficacy of four treatment regimens in patients with recurrent (unamenable to local therapy) or metastatic nasopharyngeal…
- Trial name
- NCT07070479
- Testing
- Ivonescimab, Nimotuzumab, Irinotecan liposome
- Where
- 6 sites in China
- Volunteers
- 208 people
- Sponsor
- Ming-Yuan Chen
Recurrent Nasopharyngeal Undifferentiated Carcinoma, Stage IV Nasopharyngeal Undifferentiated Carcinoma
Cyclophosphamide for Nasopharyngeal Carcinoma
There is no standard third-line systemic treatment for inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02794077
- Testing
- Cyclophosphamide
- Volunteers
- 56 people
- Sponsor
- The University of Hong Kong
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
This phase I trial is studying the side effects and best dose of sunitinib when given together with cetuximab and radiation therapy in treating patients with locally advanced or recurrent squamous cell carcinoma of the head and…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00906360
- Testing
- sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy
- Where
- 12 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898742
- Testing
- DNA and tissue microarray analysis, reverse transcriptase-polymerase chain reaction, mass spectrometry
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Nasopharyngeal Cancer
Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is carried out to find out the safety and recommended dose of CD137L-DC-EBV-VAX in nasopharyngeal cancer. CD137L-DC-EBV-VAX is a product made from one of our own immune system cells (dendritic cell, DC).
- Trial name
- NCT03282617
- Testing
- CD137L-DC-EBV-VAX
- Where
- Singapore
- Volunteers
- 55 people
- Sponsor
- National University Hospital, Singapore
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the drug's toxicity is manageable.
- Trial name
- NCT01392235
- Testing
- Famitinib
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Cancer
Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer
Nasopharyngeal cancer (NPC) is a cancer that starts at the back of the nose. Without distant spread, NPC is sensitive to radiotherapy and chemotherapy; however, if NPC relapses or spreads to other organs, treatment options are…
- Trial name
- NPC-CTL (NCT00706316)
- Testing
- EBV-Specific CTLs and CD45 Mab
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- University Health Network, Toronto
Head and Neck Cancer
Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent or…
- Trial name
- NCT00006471
- Testing
- Fenretinide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma of Unknown Primary, Head and Neck Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002507
- Testing
- mitomycin C, porfiromycin, brachytherapy
- Where
- United States
- Sponsor
- Yale University
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH in treating patients who are undergoing surgery for primary or recurrent head and neck cancer.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT00470496
- Testing
- HPPH, photodynamic therapy, conventional surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Cancer
Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00690872
- Testing
- autologous Epstein-Barr virus-specific cytotoxic T lymphocytes, carboplatin, gemcitabine hydrochloride
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- National Cancer Centre, Singapore
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
This phase I trial studies how well talactoferrin works in treating patients with relapsed or refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01528137
- Testing
- talactoferrin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Head and Neck Cancer
Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00030576
- Testing
- cisplatin, erlotinib hydrochloride
- Where
- 6 sites in Canada
- Volunteers
- 51 people
- Sponsor
- University Health Network, Toronto
Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
This partially randomized phase II trial studies giving capecitabine and vorinostat in treating patients with head and neck cancer that has come back after previous treatment or that has spread to other areas in the body.
- Conditions
- Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT01267240
- Testing
- Capecitabine, Vorinostat
- Where
- 14 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)